Ketoprofen, gel 2.5% 50 g

Pharmacotherapeutic group: Non-steroidal anti-inflammatory drug (NSAID).

ATX code: M02AA10

Pharmacological properties

Pharmacodynamics

/p>

Ketoprofen is a derivative of propionic acid and has local anti-inflammatory and analgesic effects. It inhibits the activity of cyclooxygenase-1 and cyclooxygenase-2 enzymes involved in the synthesis of prostaglandins (PG). Ketoprofen penetrates through the skin and reaches the center of inflammation, thus providing local treatment of lesions (joints, tendons, ligaments and muscles) accompanied by pain syndrome.

Pharmacokinetics

When applied topically, it is slowly absorbed through the skin and almost does not cumulate. The bioavailability of the gel is about 5%. After administration in a dose of 50-150 mg, plasma concentration after 5-8 hours is 0.08-0.15 mcg/ml. Binding to plasma proteins is approximately 99%. Metabolized by conjugation to glucuronic acid. No active metabolites are formed. Half-life period is 1-3 hours. It is excreted through the kidneys as a conjugated metabolite.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

After applying the gel to the skin, you should wash your hands thoroughly. It is inadmissible to apply the gel on damaged (open wounds) and inflamed skin. Avoid contact with the mucous membranes of the eyes (risk of irritation of the conjunctiva). Do not use with an occlusive dressing. Do not use tight clothing when using Ketoprofen-Teva.

Long-term use of the topical product may lead to increased sensitivity or local irritation. To avoid any manifestation of hypersensitivity or photosensitization, exposure to sunlight during treatment and 2 weeks after the end of treatment should be avoided. It is recommended to cover the skin areas to be treated with clothing.

Perhaps caution should be exercised when using Ketoprofen-Teva in patients with severe renal impairment.

The use of Ketoprofen-Teva should be discontinued if any skin reactions occur, including reactions when sunscreens or other cosmetic products containing the organic sunscreen octocrylene are applied at the same time.

In very rare cases, systemic side effects (hypersensitivity, bronchial asthma, gastrointestinal disorders, worsening of renal failure) may occur when using large amounts of the drug. The risk of systemic side effects increases depending on the amount of gel applied, the area of skin treated, the condition of the skin, the duration of treatment.

Influence on the ability to drive vehicles and mechanisms

The drug has no effect on the ability to drive vehicles and mechanisms.

Synopsis

Contraindications

Side effects

Possible side effects are classified according to the following frequency: very frequently (≥10%), frequently (≥1%, < 10%); infrequently (≥0.1%, < 1%); rarely (≥0.01%, < 0.1%); very rarely (< 0.01%).

Skin disorders: infrequent – skin itching, erythema, eczema; rare – photosensitization, bullous dermatitis, urticaria; very rare – contact dermatitis, angioedema.

Gastrointestinal tract:very rarely – peptic ulcer, bleeding, diarrhea.

The immune system:very rarely – anaphylactic reactions, hypersensitivity reactions.

The urinary system: very rare – aggravation of the course of renal failure.

Overdose

Pregnancy use

Since adverse effects of NSAIDs that inhibit PG synthesis on the fetal cardiopulmonary system (pulmonary hypertension, premature closure of the arterial duct) and on renal function (renal failure, combined with oligo) are known, ketoprofen should be avoided in pregnancy. Adequate and strictly controlled clinical studies in pregnant women have not been conducted. Its use in pregnancy is contraindicated.

Women who are planning to become pregnant should refrain from using ketoprofen because it may reduce the likelihood of oocyte implantation.

It is not known whether ketoprofen is excreted with breast milk, so it is not recommended to use ketoprofen while breastfeeding.

Similarities